KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent TaxesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ionis Pharmaceuticals (IONS) Current Deferred Revenue: 2009-2024

Historic Current Deferred Revenue for Ionis Pharmaceuticals (IONS) over the last 16 years, with Dec 2024 value amounting to $79.0 million.

  • Ionis Pharmaceuticals' Current Deferred Revenue rose 1.27% to $77.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $77.0 million, marking a year-over-year increase of 1.27%. This contributed to the annual value of $79.0 million for FY2024, which is 47.73% down from last year.
  • Per Ionis Pharmaceuticals' latest filing, its Current Deferred Revenue stood at $79.0 million for FY2024, which was down 47.73% from $151.1 million recorded in FY2023.
  • Over the past 5 years, Ionis Pharmaceuticals' Current Deferred Revenue peaked at $151.1 million during FY2023, and registered a low of $79.0 million during FY2024.
  • Moreover, its 3-year median value for Current Deferred Revenue was $90.6 million (2022), whereas its average is $106.9 million.
  • As far as peak fluctuations go, Ionis Pharmaceuticals' Current Deferred Revenue skyrocketed by 66.85% in 2023, and later tumbled by 47.73% in 2024.
  • Yearly analysis of 5 years shows Ionis Pharmaceuticals' Current Deferred Revenue stood at $108.4 million in 2020, then declined by 9.84% to $97.7 million in 2021, then decreased by 7.30% to $90.6 million in 2022, then soared by 66.85% to $151.1 million in 2023, then tumbled by 47.73% to $79.0 million in 2024.